Loading…
CALCIUM GLUCONATE is a brand name for Calcium Gluconate. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Parenteral administration of calcium is indicated where the pharmacological action of a high calcium ion concentration is required, as for example, in acute hypocalcaemia, and some cases of neonatal tetany. Intravenous injections of calcium have been used in the treatment of the acute colic of lead poisoning. Advice…
Verbatim from this product's MHRA label. Tap a section to expand.
5 mEq per litre. Treatment should be aimed at restoring or maintaining this level. During therapy, serum calcium levels should be monitored closely. 46 mEq of calcium. If necessary, the dose may be repeated, depending on the patient’s clinical condition.
Subsequent doses should be adjusted according to the actual serum calcium level. Paediatric patients (< 18 years) The dose and the route of administration depend on the degree of hypocalcaemia and the nature and severity of the symptoms.
In the case of mild neuromuscular symptoms oral calcium administration should be preferred. g. 45 mmol calcium per kg bw) may be necessary for a quick restoration of a normal serum calcium level. Also, if necessary, the dose may be repeated, depending on the patient’s clinical condition.
Subsequent doses should be adjusted according to the actual serum calcium level. g. in cases of calciferol deficiency. Elderly patients Although there is no evidence that tolerance of Calcium gluconate 5% w/v Solution for injection/infusion is directly affected by advanced age, factors that may sometimes be associated with ageing, such as impaired renal function and poor diet, may indirectly affect tolerance and may require a reduction in dosage.
3) in severe renal failure. See also section
The frequency of undesirable effects listed below is defined using the following convention: Very common ≥1/10 Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare ≥1/10,000 to <1/1,000 Very rare < 1/10,000 Not known: Frequency cannot be estimated from the available data Vascular and other systemic undesirable effects are likely to occur as symptoms of acute hypercalcaemia resulting from intravenous overdose or too rapid intravenous injection.
Their occurrence and frequency is directly related to the administration rate and the administered dose.
Vascular disorders Not known:
Hypotension, circulatory collapse (possibly fatal), flushing, mainly after too rapid injection. Cardiac disorders Not known: bradycardia, cardiac arrhythmia.
Gastrointestinal disorders Not known:
Nausea, vomiting.
General disorders and administration site conditions Not known:
Heat sensations, sweating Ceftriaxone-calcium salt precipitation Rarely, severe, and in some cases fatal, adverse reactions have been reported in preterm and full-term newborns (aged < 28 days) who had been treated with intravenous ceftriaxone and calcium.
Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. 4).
Adverse reactions only occurring with improper administration technique:
Not known: Soft tissue calcification due to extravasation of calcium solutions has been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store.
4. 5 – 1 g calcium gluconate / kg bw / d) over 1 – 2 days. Heart rate should be monitored during the infusion. The IV site should also be watched closely because tissue infiltration by a calcium solution is irritating and may cause local tissue damage or necrosis.
Acute colic of lead poisoning Adult and paediatric patients (< 18 years) Advice should be sought from specialist centres (National Poisons Information Service, tel: 111) regarding the treatment of symptoms of acute lead poisoning. Fluoride poisoning Adult and paediatric patients (< 18 years) Advice should be sought from specialist centres (National Poisons Information Service, tel: 111) regarding treating patients with this condition.
Calcium gluconate regime for hypocalcaemia in fluoride poisoning:
Immediate: - give 20 mL of 5% calcium gluconate intravenously on presentation, repeat at 1 hour, or - give 60 mL of 5% calcium gluconate intravenously if tetany present. Maintenance: - Maintain serum calcium with intravenous 5% calcium gluconate 20 mL every 4 hours, adjusting according to frequent serum calcium concentrations.
Mild to moderate dermal toxicity due to hydrofluoric acid/fluoride exposure:
Subcutaneous calcium gluconate (5%) for dermal exposure of hydrofluoric acid > 20%. 5 mL of 5% calcium gluconate. In the case of significant burn due to hydrofluoric acid/fluoride exposure, calcium salts may be administered intravenously (for systemic toxicity) or intra-arterially (for hand burns predominantly).
- 20 mL of 5% calcium gluconate plus heparin 5000 units in a total volume of 40 mL is administered intravenously. 9% sodium chloride solution is intra- arterially infused over 4 h. Hypocalcaemia during transfusion Adults Calcium should be administered during massive transfusion if Ca2+ concentration is low, in order to preserve normocalcaemia.
1. g. 5). 4) is contraindicated. 2)
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Calcium Gluconate in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
20 mL of Calcium gluconate 5% w/v Solution for injection/infusion IV diluted in 100 mL D5W (5% Glucose in water), given over 10 min or 20-40 mL Calcium gluconate 5% w/v Solution for injection/infusion for each 500 mL of blood infused.
Pediatric patients (< 18 years) During transfusion / exchange transfusion the patient’s clinical condition and the calcium serum concentration have to be monitored, and a clinically significant hypocalcaemia should be treated according to dosing recommendations for acute hypocalcaemia.
Method of administration The patient should be in the lying position and should be closely observed during injection. Monitoring should include heart rate or ECG. Extravasation must be avoided; the injection site should be monitored carefully.
Adults Slow intravenous injection. For the intramuscular route, if intravenous injection is not possible, only the 10% w/v solution should be used. 45 mmol of calcium) per minute. Paediatric patients (<18 years) Only slow intravenous injection or intravenous infusion (both after dilution), in order to achieve sufficiently low administration rates and to avoid irritation/necrosis in case of accidental extravasation.
6) of Calcium gluconate 5% w/v Solution for injection/infusion in children and adolescents. 5 ml Calcium gluconate 5% w/v Solution for injection/infusion per phalanx should not be exceeded. 1. g. 5). 4) is contraindicated. 4 Special warnings and precautions for use Plasma calcium levels and calcium excretion should be monitored when calcium is administered parenterally, especially in children, in chronic renal failure or where there is evidence of calculi formation within the urinary tract.
75 mmol per litre or if 24 hour urinary calcium excretion exceeds 5 mg / kg, treatment should be discontinued immediately as cardiac arrhythmias may occur at these levels. 3. In the exceptional case of intravenous administration of calcium gluconate to patients receiving cardiac glycosides, adequate cardiac monitoring is mandatory and emergency treatment of cardiac complications such as serious arrhythmias must be available.
Intravenous injections should be accompanied by heart rate or ECG control because bradycardia with vasodilatation or arrhythmia can occur when calcium is administered too quickly. Renal impairment may be associated with hypercalcaemia and secondary hyperparathyroidism.
Therefore, in patients with renal impairment, parenteral calcium should be administered only after careful assessment of the indication and the calcium-phosphate balance should be monitored. Calcium salts should be used with caution in patients with nephrocalcinosis.
Care is also required in […]